Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919169 | 0.93 | PPARD (0.49) | PPARDOPRK1OPRM1BCL2L1BAK1 | |
| SCHEMBL4917186 | 0.92 | PPARD (0.49) | PPARDOPRK1OPRM1BCL2L1BAK1 | |
| SCHEMBL4909563 | 0.85 | PPARD (0.49) | PPARDCNR2 | |
| SCHEMBL4913994 | 0.85 | PPARD (0.41) | PPARDOPRK1OPRM1BCL2L1BAK1 | |
| SCHEMBL14006364 | 0.83 | OPRK1 (0.41) | PPARDOPRK1OPRM1CNR2 | |
| SCHEMBL4916382 | 0.80 | PPARD (0.54) | PPARDCNR2CXCR3 | |
| SCHEMBL4918849 | 0.79 | PPARD (0.41) | PPARDL3MBTL1 | |
| SCHEMBL4919179 | 0.78 | PPARD (0.51) | PPARDCNR2CXCR3 | |
| SCHEMBL4917200 | 0.77 | PPARD (0.50) | PPARDCNR2CXCR3 | |
| SCHEMBL14541369 | 0.75 | PPARD (0.40) | PPARDBCL2L1BAK1CXCR3GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | KALYPSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | KALYPSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | KALYPSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287477-A1 | Novel Compounds as Modulators of Ppar | PPARG, PPARA, PPARD | PPARD 3/4885OPRK1 1063/4885OPRM1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.